ES2907125T3 - Preparación de HGF adecuada para el tratamiento de trastornos neurológicos - Google Patents

Preparación de HGF adecuada para el tratamiento de trastornos neurológicos Download PDF

Info

Publication number
ES2907125T3
ES2907125T3 ES15840062T ES15840062T ES2907125T3 ES 2907125 T3 ES2907125 T3 ES 2907125T3 ES 15840062 T ES15840062 T ES 15840062T ES 15840062 T ES15840062 T ES 15840062T ES 2907125 T3 ES2907125 T3 ES 2907125T3
Authority
ES
Spain
Prior art keywords
hgf
protein
preparation
injection
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15840062T
Other languages
English (en)
Spanish (es)
Inventor
Kazuhiro Fukuta
Hayao Inoue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kringle Pharma Inc
Original Assignee
Kringle Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kringle Pharma Inc filed Critical Kringle Pharma Inc
Application granted granted Critical
Publication of ES2907125T3 publication Critical patent/ES2907125T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
ES15840062T 2014-09-10 2015-08-27 Preparación de HGF adecuada para el tratamiento de trastornos neurológicos Active ES2907125T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014184475 2014-09-10
PCT/JP2015/074310 WO2016039163A1 (ja) 2014-09-10 2015-08-27 神経疾患の治療に適したｈｇｆ製剤

Publications (1)

Publication Number Publication Date
ES2907125T3 true ES2907125T3 (es) 2022-04-22

Family

ID=55458917

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15840062T Active ES2907125T3 (es) 2014-09-10 2015-08-27 Preparación de HGF adecuada para el tratamiento de trastornos neurológicos

Country Status (10)

Country Link
US (2) US10213485B2 (da)
EP (1) EP3192524B1 (da)
JP (2) JP6281992B2 (da)
KR (1) KR101950916B1 (da)
CN (1) CN106714823A (da)
CA (1) CA2958342C (da)
DK (1) DK3192524T3 (da)
ES (1) ES2907125T3 (da)
PT (1) PT3192524T (da)
WO (1) WO2016039163A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016039163A1 (ja) * 2014-09-10 2016-03-17 クリングルファーマ株式会社 神経疾患の治療に適したｈｇｆ製剤
AU2017342555A1 (en) * 2016-10-14 2019-05-30 Children's Medical Center Corporation Compositions and methods for treating diseases and disorders of the central nervous system
CN110913872B (zh) 2017-01-17 2023-08-04 儿童医疗中心有限公司 治疗溶酶体贮积疾病及病症的组合物和方法
KR102245539B1 (ko) * 2018-02-12 2021-04-29 주식회사 지앤피바이오사이언스 코어-쉘 구조의 마이크로 입자를 유효성분으로 포함하는 성장인자 유전자 발현 증가용 조성물
EP3823982A4 (en) * 2018-07-17 2022-04-13 Helixmith Co., Ltd TREATMENT OF NEUROPATHY WITH IGF-1-ENCODING DNA CONSTRUCTS AND HGF-ENCODING DNA CONSTRUCTS
CN109535243B (zh) * 2019-01-07 2019-09-24 北京诺思兰德生物技术股份有限公司 人肝细胞生长因子突变体及其应用
KR20240035394A (ko) 2021-05-14 2024-03-15 클라리스 바이오쎄라퓨틱스, 인코포레이티드 안질환 치료를 위한 성장 인자 조성물

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ232813A (en) 1989-03-10 1992-08-26 Snow Brand Milk Products Co Ltd Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons
JP3680114B2 (ja) * 1993-09-17 2005-08-10 敏一 中村 脳神経障害治療剤
JP3927248B2 (ja) 1995-07-11 2007-06-06 第一製薬株式会社 Ｈｇｆ凍結乾燥製剤
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
ATE359809T1 (de) * 1999-05-31 2007-05-15 Mitsubishi Chem Corp Gefriergetrocknete hgf-präparationen
US20030176347A1 (en) 2003-05-14 2003-09-18 Toshikazu Nakamura Remedies for amyotrophic lateral sclerosis
JP5442173B2 (ja) 2000-09-14 2014-03-12 敏一 中村 筋萎縮性側索硬化症治療剤
NZ530545A (en) * 2001-07-11 2006-10-27 Maxygen Holdings Ltd Specific conjugates comprising a polypeptide exhibiting G-CSF activity and a non-polypeptide moiety
GB0202633D0 (en) * 2002-02-05 2002-03-20 Delta Biotechnology Ltd Stabilization of protein preparations
WO2004084934A1 (ja) * 2003-03-26 2004-10-07 Kringle Pharma Inc. 喘息治療剤
US20070021335A1 (en) 2003-10-14 2007-01-25 Satoshi Takeo Agent for improving mental disorders
US7265092B2 (en) * 2004-09-30 2007-09-04 Kai Pharmaceuticals, Inc. Pharmaceutical formulation
DK1855661T3 (da) * 2005-03-07 2011-08-15 Mondobiotech Ag Aviptadilformulering
JP5051725B2 (ja) 2006-04-20 2012-10-17 国立大学法人大阪大学 ポリグルタミン病の治療剤又は発病抑制剤
CL2007003661A1 (es) * 2006-12-18 2008-07-18 Genentech Inc Regiones de cadena pesada variable y liviana variable; acidos nucleicos que las codifican; metodo de produccion; anticuerpos anti-notch3 que las comprenden; y uso de los anticuerpos para tratar enfermedades relacionadas con el receptor notch3.
WO2008102452A1 (ja) 2007-02-22 2008-08-28 Kringle Pharma Inc. Ｈｇｆ製剤
WO2008105088A1 (ja) 2007-02-28 2008-09-04 Keio University 脊髄損傷治療薬剤
WO2010008023A1 (ja) * 2008-07-18 2010-01-21 クリングルファーマ株式会社 骨延長促進剤
US8927493B2 (en) * 2008-10-10 2015-01-06 Kringle Pharma, Inc. Promoter for regeneration of tendon-bone junction tissue or ligament-bone junction tissue
CN101785856B (zh) 2009-01-22 2012-06-06 齐鲁制药有限公司 稳定等渗的去氨普酶α1或其突变体制剂
JP2011173916A (ja) * 2011-05-02 2011-09-08 Toshiichi Nakamura 筋萎縮性側索硬化症治療剤
EA201590582A1 (ru) * 2012-12-07 2016-01-29 Шир Хьюман Дженетик Терапис, Инк. Способы и композиции для лечения мукополисахаридоза типа iiia с использованием интратекального введения
EP2970396B1 (en) * 2013-03-15 2022-02-23 Biological Mimetics, Inc. Immunogenic human rhinovirus (hrv) compositions
WO2016039163A1 (ja) * 2014-09-10 2016-03-17 クリングルファーマ株式会社 神経疾患の治療に適したｈｇｆ製剤

Also Published As

Publication number Publication date
JP2018044000A (ja) 2018-03-22
EP3192524B1 (en) 2021-12-29
US10213485B2 (en) 2019-02-26
WO2016039163A1 (ja) 2016-03-17
PT3192524T (pt) 2022-02-17
KR20170054465A (ko) 2017-05-17
JPWO2016039163A1 (ja) 2017-06-22
CA2958342A1 (en) 2016-03-17
US20190117732A1 (en) 2019-04-25
DK3192524T3 (da) 2022-02-14
CN106714823A (zh) 2017-05-24
EP3192524A1 (en) 2017-07-19
CA2958342C (en) 2019-09-24
EP3192524A4 (en) 2018-07-04
US10702582B2 (en) 2020-07-07
US20170333527A1 (en) 2017-11-23
JP6281992B2 (ja) 2018-02-21
KR101950916B1 (ko) 2019-02-21

Similar Documents

Publication Publication Date Title
ES2907125T3 (es) Preparación de HGF adecuada para el tratamiento de trastornos neurológicos
ES2408784T3 (es) Preparaciones liofilizadas de HGF
ES2279522T3 (es) Preparaciones liofilizadas de hgf.
ES2282161T3 (es) Formulaciones de glp-2.
ES2374712T3 (es) Proteína antisecretora para uso en el tratamiento del síndrome compartimental.
ES2952519T3 (es) Polipéptidos cíclicos, su procedimiento de obtención y su aplicación en terapéutica
JP4255515B2 (ja) 安定化された成長ホルモン処方物およびその製造方法
ES2946600T3 (es) Formulaciones líquidas de daptomicina
KR101492511B1 (ko) Ｈｇｆ 제제
ES2385888T3 (es) Solución acuosa estable de eritropoyetina humana que no contiene albúmina sérica
ES2605022T3 (es) Una formulación líquida estable de la hormona del crecimiento humana
CA3011609C (en) A lyophilised pharmaceutical formulation and its use
WO2007009404A1 (es) Formulaciones nasales de eporh con bajo contenido de ácido siálico para el tratamiento de enfermedades del sistema nervioso central.
BR112020000115A2 (pt) sais farmaceuticamente aceitáveis de polipeptídeos e uso dos mesmos
ES2268166T3 (es) Composicion farmaceutica estable que comprende eritropoyetina.
CN115038431A (zh) 达托霉素制剂
JP5265514B2 (ja) Ｈｇｆ製剤
KR20180122144A (ko) 인슐린 비강 전달용 제제